Crosscheck

Your medical. Crosschecked.

Eyes

Lifitegrast (ophthalmic)

Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist
Other names: Xiidra

FAA guidance

Acceptable with conditions.

Wait

24 hours

after the first dose

There is more to this wait.

Source: FAA, MedGuide (FAA Office of Aerospace Medicine medication reference). FAA date 1 October 2026. Checked by Crosscheck 14 October 2026

The FAA's MedGuide lists lifitegrast (ophthalmic) (Xiidra) as allowed, for dry eye disease, with a wait of 24 hours after the first dose; after each dose, no flying or safety-related duties while experiencing blurry vision or headache; and none after the final dose, used as prescribed.

Track your medications
More detail: lifitegrast (ophthalmic)The rest of Crosscheck's reading, in plain wordsOpen

Wait

  • after each dose, no flying or safety-related duties while experiencing blurry vision or headache

The MedGuide defines allowed as acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present, and says wait times are not determined solely by the medication: an extended observation period may be required to verify clinical stability of the condition.

  • 24 hours after the first dose: ground observation
Show the FAA's words: lifitegrast (ophthalmic)The official FAA wording: three passages, each with its document and dateOpen
FAA, MedGuide (FAA Office of Aerospace Medicine medication reference) · FAA date 1 October 2026
Generic: lifitegrast (ophthalmic)
Brand Name: Xiidra
Drug Class: Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist
Underlying Condition: Dry eye disease
Use: ALLOW
INITIAL Wait Time (after first dose): 24 hours
SUBSEQUENT Dose Wait Time (after each dose): Do not fly or perform SRD while experiencing blurry vision or headache.
DISCONTINUATION Wait Time (after final dose): None
Frequency Use Limit: As prescribed
FAA, MedGuide (FAA Office of Aerospace Medicine medication reference) · FAA date 1 October 2026
ALLOWED: The medication is acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present.
FAA, MedGuide (FAA Office of Aerospace Medicine medication reference) · FAA date 1 October 2026
Underlying Condition: Evaluating medication use requires considering the impact of safety of flight from both the medication and underlying condition. Wait times are not determined solely by the medication; an extended observation period may be required to verify clinical stability of the condition.
Sources and dates: lifitegrast (ophthalmic)One FAA document, with the FAA's date and when Crosscheck checked itOpen

See also

Medication guidance alone does not determine whether a pilot is medically qualified to fly. The underlying condition, dosage, side effects, medication combinations, and certification history may affect FAA eligibility.

For informational purposes only. Not legal or medical advice.